Medical research is an ongoing phenomenon, and companies achieving the core of what makes animals better are always worth of attention.
Monday, Lexagene Holdings Inc (TSX-Venture:LXG) announced Monday that as part of the Company’s previously announced pilot clinical study, the LX genetic analyzer technology, in a fully automated manner, successfully detected all six of the known pathogens in 107 canine urine samples tested.
Lexagene, out of Beverly, Mass., is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers. LexaGene’s LX genetic analyzer will provide the first technology for in-hospital use that provides rapid, sensitive, and broad-spectrum testing, which will help veterinarians reduce morbidity and mortality rates, lower healthcare costs, and improve antibiotic stewardship.
CEO Jack Regan proclaimed, "This is a monumental moment for the organization, as we have concluded our pilot study and are extremely pleased with the performance of the LX analyzer.
"This news represents the tip of the iceberg for what is to come from LexaGene as we continue to demonstrate how our technology outperforms the current standard for testing."
Stocks in Lexagene gained six cents or 9.2%, by noon ET Monday, to 71 cents, on volume of 113,000 shares.
